Patents by Inventor Venkateswararao Eeda

Venkateswararao Eeda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250049968
    Abstract: Analogs and derivatives of omecamtiv mecarbil (OM), including an 18F-labeled analog, and methods of synthesis thereof. Cardiac myosin targeting vectors comprising a lipid anchoring/solubilizing moiety conjugated to a head made of OM or the OM analog or derivative. Liposomes comprising a cardiac-treating cargo molecule and the cardiac myosin targeting vector. Methods of treating a cardiac condition or disease in a subject by administering to the subject the cardiac-treating cargo molecule and the cardiac myosin targeting vector. Methods of synthesizing an 18F-labeled analog of OM.
    Type: Application
    Filed: October 21, 2024
    Publication date: February 13, 2025
    Applicant: The Board of Regents of the University of Oklahoma
    Inventors: Venkateswararao Eeda, Vibhudutta Awasthi
  • Publication number: 20240279231
    Abstract: The compound DMX-5804, IUPAC name 5-(4-(2-methoxyethoxy)phenyl)-7-phenyl-3,4a,7,7a-tetrahydro-4H-pyrrolo[2,3-d]pyrimidin-4-one, is a potent and selective inhibitor of mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4). The present disclosure describes a scalable and practical synthesis process for making DMX-5804. The process (1) doesn't rely on transition metals, (2) has reduced duration of reactions, (3) is streamlined with significantly improved yields using low cost raw materials, (4) includes no microwave-assisted reactions, (5) does not require column purification, and (6) generally results in crystalized products having over a 95% purity in each step. The present disclosure also describes DMX-5804 analogs and derivatives for use in inhibiting MAP4K4, and scalable and practical processes for making such DMX-5804 analogs.
    Type: Application
    Filed: May 20, 2022
    Publication date: August 22, 2024
    Applicant: The Board of Regents of the University of Oklahoma
    Inventors: Vibhudutta Awasthi, Venkateswararao Eeda
  • Patent number: 11999677
    Abstract: Benzylamino-oxoethyl benzamide compounds for use in treating diseases and conditions associated with abnormal cell function related to endoplasmic reticulum (ER) stress. For example, the compounds can be used as suppressors of ER stress-induced pancreatic ?-cell dysfunction and death, for example in the treatment of Type 1 and Type 2 diabetes. The compounds can also be used in treatments for chronic heart disease, neurodegenerative diseases, retinal degeneration, and other metabolic disorders associated with ER stress.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: June 4, 2024
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Weidong Wang, Venkateswararao Eeda
  • Publication number: 20240150286
    Abstract: Compounds and methods for treating insulin resistance, obesity, Type 2 diabetes, Nonalcoholic fatty liver disease (NAFLD), and peroxisome proliferator-activated receptor gamma (PPARy) serine 273 phosphorylation in subjects in need of such therapy.
    Type: Application
    Filed: October 25, 2023
    Publication date: May 9, 2024
    Inventors: Venkateswararao Eeda, Weidong Wang, Dan Wu
  • Publication number: 20230348396
    Abstract: Hydroxybenzamide derivative compounds having ?-cell protective activity against ER stress, and methods of their use in treating diabetes and other conditions and diseases associated with ER stress. In one non-limiting embodiment, the derivative is 3-hydroxy-N-(4-(trifluoromethyl)benzyl)benzamide.
    Type: Application
    Filed: April 28, 2023
    Publication date: November 2, 2023
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
    Inventors: Venkateswararao EEDA, Weidong WANG
  • Publication number: 20220162157
    Abstract: Benzylamino-oxoethyl benzamide compounds for use in treating diseases and conditions associated with abnormal cell function related to endoplasmic reticulum (ER) stress. For example, the compounds can be used as suppressors of ER stress-induced pancreatic ?-cell dysfunction and death, for example in the treatment of Type 1 and Type 2 diabetes. The compounds can also be used in treatments for chronic heart disease, neurodegenerative diseases, retinal degeneration, and other metabolic disorders associated with ER stress.
    Type: Application
    Filed: February 8, 2022
    Publication date: May 26, 2022
    Inventors: Weidong Wang, Venkateswararao Eeda
  • Publication number: 20200071264
    Abstract: Benzylamino-oxoethyl benzamide compounds for use in treating diseases and conditions associated with abnormal cell function related to endoplasmic reticulum (ER) stress. For example, the compounds can be used as suppressors of ER stress-induced pancreatic ?-cell dysfunction and death, for example in the treatment of Type 1 and Type 2 diabetes. The compounds can also be used in treatments for chronic heart disease, neurodegenerative diseases, retinal degeneration, and other metabolic disorders associated with ER stress.
    Type: Application
    Filed: September 3, 2019
    Publication date: March 5, 2020
    Inventors: Weidong Wang, Venkateswararao Eeda